Myriad Genetics Files 8-K for Regulatory Updates

TL;DR

MYGN filed an 8-K, likely with new disclosures. Keep an eye on their news.

AI Summary

Myriad Genetics, Inc. filed an 8-K on September 4, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing pertains to events occurring on or before September 3, 2024. The company is incorporated in Delaware and headquartered in Salt Lake City, Utah.

Why It Matters

This 8-K filing indicates that Myriad Genetics is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not inherently signal significant risk.

Key Players & Entities

• MYRIAD GENETICS INC (company) — Registrant
• September 4, 2024 (date) — Date of Report
• September 3, 2024 (date) — Date as of Change
• Salt Lake City, Utah (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar

Filing Documents

• mygn-20240904.htm (8-K) — 29KB
• 0000899923-24-000045.txt ( ) — 176KB
• mygn-20240904.xsd (EX-101.SCH) — 2KB
• mygn-20240904_def.xml (EX-101.DEF) — 14KB
• mygn-20240904_lab.xml (EX-101.LAB) — 25KB
• mygn-20240904_pre.xml (EX-101.PRE) — 15KB
• mygn-20240904_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

ITEM 7.01 Regulation FD Disclosure. Myriad Genetics, Inc. (the "Company") previously reported the initial results of a retrospective, multi-part, economic utility study linking patients who had received GeneSight testing to administrative insurance claims from a nationwide data warehouse in the United States. The Company partnered with a leading third-party vendor to conduct the multi-part study. As initially reported in April 2024, the results of part one of the study, the full results of which the Company plans to publish in the near future, showed that, in the first 180 days after GeneSight testing, the percentage of patients with hospitalizations for any reason and psychiatric-related hospitalizations decreased by 29% and 39%, respectively. Based on prior GeneSight studies, the Company hypothesized that GeneSight testing had contributed to the reduction in hospitalizations. Part one of the study, however, did not include a non-GeneSight control group to evaluate whether or to what extent GeneSight testing was the cause of the reduction in hospitalizations. The Company planned to conduct an additional analysis of the administrative insurance claims data with a non-GeneSight control group with the goal to test the Company's hypothesis and share the results of this second part of the study in the second half of 2024. Part two of this study was designed to analyze the hospital resource utilization and costs of a group of patients who had received GeneSight testing compared to a matched control group of patients who had not received GeneSight testing. To identify the non-GeneSight control group, the Company directed the third-party vendor to review its data warehouse to identify a group of patients that best matched the characteristics of the GeneSight patient group. After the best-matched non-GeneSight control group was identified using the available data, the Company identified significant disparities between the GeneSight patient group and this non-GeneSight

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: September 4, 2024 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR